<DOC>
	<DOCNO>NCT00654966</DOCNO>
	<brief_summary>Urotensin II ( U-II ) newly discover protein may play important role human health disease . U-II found potent vasoconstrictor ( narrow blood vessel ) therefore may involve important disease chronic heart failure - CHF ( weak heart muscle disease ) . Many vasoconstrictor find effect key organ heart . Preliminary data group demonstrate true U-II . Recent evidence show CHF , U-II level blood increase . The propose study seek determine effect block possible downstream mediator U-II blood vessel administration soluble epoxide hydrolase inhibitor ( sEHI ) . There 2 study group 1 ) Healthy volunteer , 2 ) CHF patient . Each arm study run independently require 16 participant ( 16 normal subject 16 CHF subject ) . Participants screen ensure eligible . CHF patient require withdraw CHF medication 24 hour prior study day ( except diuretic ) . On study day , sEHI administer skin participant 3 asceding dosage . The technique use iontophoresis . This non invasive technique small amount compound place skin forearm . The drug deliver across skin pass small electric current area . The change blood flow measure analysed . We also administer U-II agonist , noradrenaline , distilled water ( via iontophoresis ) . Noradrenaline use positive constrictor control . Change blood flow assess Laser Doppler Velocimetry . If find sEHI able prevent blood vessel constriction CHF patient , may represent major therapeutic advance management CHF .</brief_summary>
	<brief_title>Evaluation Effects Urotensin-II Soluble Epoxide Hydrolase Inhibitors Skin Microvessel Tone Patients With Heart Failure , Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Confirmed write informed consent . Male/Female 18 80 year age . Females must nonpregnant , nonlactating use reliable mean contraception ( surgical sterilisation barrier method condom ) . The oral contraceptive pill exclusion study . Patients CHF require leave ventricular fractional shortening [ LVFS ] &lt; 22 % LVEF &lt; 40 % New York Heart Association functional class [ NYHA FC ] IIIII symptom Body mass index ( BMI ) 1835 kg/m2 . Screening clinical laboratory test include liver function test HbA1c within normal reference range investigative site . Electrocardiogram ( ECG ) result consider within normal limit , determine Investigator . Smokers History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , neurological , disorder capable alter absorption , metabolism , elimination drug , constitute risk factor expose study medication . Those require concomitant medication affect cardiovascular endothelial function blood pressure control ( eg cholesterol lower medication , hormone replacement therapy , aspirin , NSAIDS ) . Patients receive Hormone Replacement Therapy . Known allergy hypersensitivity urotensin urotensin receptor antagonists excipients , relate drug , history relevant adverse drug reaction origin . Regular alcohol intake great 14 units/week unwilling comply alcohol prohibition duration study ( 1 unit alcohol equivalent : 12 ounce beer , 4 ounce wine , 1 ounce 50proof hard liquor ) . History drug abuse . Screening biochemistry &gt; 20 % outside normal limit . Patients think terminally ill immunocompromised Patients previously enrol study receive experimental medication last 4 week . Patients unlikely comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Urotensin II</keyword>
	<keyword>Soluble epoxide hydrolase</keyword>
	<keyword>Iontophoresis</keyword>
	<keyword>Healthy volunteer</keyword>
</DOC>